Abstract #2273
Minimum sample size requirements for rCBV measures in patient glioblastoma trials
Melissa A Prah 1 , Steven M Stufflebeam 2 , Eric S Paulson 1,3 , Jayashree Kalpathy-Cramer 2 , Elizabeth R Gerstner 4 , Tracy T Batchelor 4 , Daniel P Barboriak 5 , Bruce Rosen 2 , and Kathleen M Schmainda 1,6
1
Radiology, Medical College of Wisconsin,
Milwaukee, WI, United States,
2
Radiology,
Massachusetts General Hospital, Charlestown, MA, United
States,
3
Radiation
Oncology, Medical College of Wisconsin, Milwaukee, WI,
United States,
4
Neurology,
Massachusetts General Hospital, Boston, MA, United
States,
5
Radiology,
Duke University Medical Center, Durham, NC, United
States,
6
Biophysics,
Medical College of Wisconsin, Milwaukee, WI, United
States
Measures of relative cerebral blood volume (rCBV) have
shown to be immensely useful in assessing brain tumor
vascularity. This has led to increased interest in the
use of rCBV as a biomarker of clinical outcome or in
research. This work provides an estimate of the minimum
sample-size requirements to power a clinical imaging
trial involving glioblastoma patients for six of the
most commonly used rCBV estimation methods in order to
detect a parameter change of 10% or 20%. Using these
results, the efficiency of clinical trials may be
improved with methods requiring considerably fewer
participants to address a given hypothesis.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
